Anti-IgE therapy of asthma

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1157-1160

  Chung, K Fan ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allergic rhinitis; Asthma; Fc RI; IgE; Monoclonal antibody

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; AUTACOID; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; FC RECEPTOR FOR IMMUNOGLOBULIN E; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; BASOPHIL DEGRANULATION; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; HIGH RISK PATIENT; HOUSE DUST ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR RELEASE; META ANALYSIS; MORBIDITY; PATHOGENESIS; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARMACODYNAMICS; PROTEIN BINDING; PROVOCATION TEST; REVIEW; SIDE EFFECT;

ALLERGENS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; CHILD; HUMANS; IMMUNOGLOBULIN E; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, FC; RHINITIS, ALLERGIC, SEASONAL;

EID: 0036707308     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Chang TW: The pharmacological basis of anti-IgE therapy. Nat Biotechnol (2000) 18:157-162. Excellent review of the rationale and potential mechanisms and benefits of anti-IgE therapy.
2. Rajakulasingam K, Durham SR, O'Brien F, Humbert M, Barata LT, Reece L, Kay AB, Grant JA: Enhanced expression of high-affinity IgE receptor (FcεRI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. J Allergy Clin Immunol (1997) 100:78-86.
3. Pollart SM, Chapman MD, Fiocco GP, Rose G, Platts-Mills TA: Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol (1989) 83:875-882.
4. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. New Engl J Med (1989) 320:271-277.
5. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. New Engl J Med (1991) 325:1067-1071.
6. Peat JK, Toelle BG, Dermand J, Van Den Berg R, Britton WJ, Woolcock AJ: Serum IgE levels, atopy, and asthma in young adults: Results from a longitudinal cohort study. Allergy (1996) 51:804-810.
7. Sunyer J, Anto JM, Sabria J, Roca J, Morell F, Rodriguez Roisin R, Rodrigo MJ: Relationship between serum IgE and airway responsiveness in adults with asthma. J Allergy Clin Immunol (1995) 95:699-706.
8. Bacharier LB, Geha RS: Regulation of IgE synthesis: The molecular basis and implications for clinical modulation. Allergy Asthma Proc (1999) 20:1-8.
9. Vercelli D, Jabara HH, Arai K, Geha RS: Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. J Exp Med (1989) 169:1295-1307.
10. Helm BA, Spivey AC, Padlan EA: Peptide blocking of IgE/receptor interaction: Possibilities and pitfalls. Allergy (1997) 52:1155-1169.
11. Jardieu P: Anti-IgE therapy. Curr Opin Immunol (1995) 7:779-782.
12. Kitani S, Kraft D, Fischler C, Mergenhagen SE, Siraganian RP: Inhibition of allergic reactions with monoclonal antibody to the high affinity IgE receptor. J Immunol (1988) 140:2585-2588.
13. Haba S, Nisonoff A: Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc Natl Acad Sci USA (1990) 87:3363-3367.
14. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM: Humanization of an antibody directed against IgE. J Immunol (1993) 151:2623-2632.
15. Come J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E et al: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J Clin Invest (1997) 99:879-887. First description of the pharmacokinetics on an anti-IgE antibody in humans.
16. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, Kinet JP, Galli SJ: IgE enhances mouse mast cell FcεRI expression in vitro and in vivo: Evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med (1997) 185:663-672.
17. MacGlashan D Jr, Xia HZ, Schwartz LB, Gong J: IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcεRI in human basophils. J Leukoc Biol (2001) 70:207-218.
18. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 158:1438-1445. Potentially the most important effect of anti-IgE therapy that could underlie the clinical benefits observed.
19. MacGlashan D, Lichtenstein LM, McKenzie-White J, Chichester K, Henry AJ, Sutton BJ, Gould HJ: Upregulation of FcεRI on human basophils by IgE antibody is mediated by interaction of IgE with FcεRI. J Allergy Clin Immunol (1999) 104:492-498.
20. Togias A, Corren J, Shapiro G: Anti-IgE treatment reduces skin test reactivity. J Allergy Clin Immunol (1998) 101:S171.
21. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A et al: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response [see comments]. Am J Respir Crit Care Med (1997) 155:1835-1840. First piece of evidence showing the effectiveness of this new therapy.
22. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med (1997) 155:1828-1834. First piece of evidence showing the effectiveness of this new therapy.
23. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med (1999) 341:1966-1973. Clinical efficacy in steroid-dependent asthmatic children.
24. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della CG: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J (2001) 18:254-261. Clinical trial in moderate-to-severe asthma.
25. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol (2001) 108:184-190. Clinical trial in moderate-to-severe asthma.
26. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics (2001) 108:E36.
27. Holgate ST, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin (2001) 17:233-240. Meta-analysis of trials to date in asthma, supporting particular beneficial effects in patients at risk of severe morbidity.
28. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandstrom T: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol (2000) 106:253-259.
29. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Adelman DC: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol (1997) 100:110-121. Efficacy of anti-IgE in allergic rhinitis dependent on the level of free IgE achieved with anti-IgE treatment.
30. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Grave M, Hultsch T, Wahn U: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol (2002) 109:274-280.